Iran has produced a recombinant factor VIII drug, and hopes to mass-produce the medicine in the current Iranian calendar year, which started on March 20, 2016.
The drug, also dubbed AHF, is one of the proteins involved in blood coagulation. It is a protein which helps blood coagulation in consecutive reactions.
Lack of the factor causes Hemophilia A.
While there are over 100 recombinant drugs in the world, Factor VIII is one of the most complicated ones.
Iranian researchers made Coagulation factor 8 through a recombinant method. The researchers used biotechnology and genetic engineering and produced the efficient gene.
The product was processed in a reactor through biotechnology and biotechnology engineering.
The country would save at least $60m if it could mass-produce the drug.